Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Lakshmikant Gupta"'
Autor:
Krishnarup Ghoshdastidar, Hoshang Patel, Hitesh Bhayani, Ankit Patel, Kinjal Thakkar, Dinesh Patel, Manoranjan Sharma, Jaideep Singh, Jogeswar Mohapatra, Abhijit Chatterjee, Dipam Patel, Rajesh Bahekar, Rajiv Sharma, Lakshmikant Gupta, Nirmal Patel, Poonam Giri, Nuggehally R. Srinivas, Mukul Jain, Debdutta Bandyopadhyay, Pankaj R. Patel, Ranjit C. Desai
Publikováno v:
Pharmacology Research & Perspectives, Vol 8, Iss 4, Pp n/a-n/a (2020)
Abstract Bruton's tyrosine kinase (BTK) plays a central and pivotal role in controlling the pathways involved in the pathobiology of cancer, rheumatoid arthritis (RA), and other autoimmune disorders. ZYBT1 is a potent, irreversible, specific BTK inhi
Externí odkaz:
https://doaj.org/article/426ccabb23744fc0aceb0a7d29b505f0
Autor:
Dinesh Patel, Dipam Patel, Pankaj R. Patel, Jogeswar Mohapatra, Hoshang Patel, Krishnarup Ghoshdastidar, Abhijit Chatterjee, Rajiv P. Sharma, Mukul R. Jain, Jaideep Singh, Manoranjan Sharma, Poonam Giri, Kinjal Thakkar, Debdutta Bandyopadhyay, Rajesh Bahekar, Hitesh Bhayani, Ranjit C. Desai, Ankit Patel, Lakshmikant Gupta, Nuggehally R. Srinivas, Nirmal Patel
Publikováno v:
Pharmacology Research & Perspectives, Vol 8, Iss 4, Pp n/a-n/a (2020)
Pharmacology Research & Perspectives
Pharmacology Research & Perspectives
Bruton's tyrosine kinase (BTK) plays a central and pivotal role in controlling the pathways involved in the pathobiology of cancer, rheumatoid arthritis (RA), and other autoimmune disorders. ZYBT1 is a potent, irreversible, specific BTK inhibitor tha
Autor:
Poonam Giri, Vipul Joshi, Nuggehally R. Srinivas, Nirmal Patel, Lakshmikant Gupta, Sneha Naidu, Shyamkumar Giri
Publikováno v:
Drug Metabolism Letters
Background: The use of polypharmacy in the present day clinical therapy has made the identification of clinical drug-drug interaction risk an important aspect of drug development process. Although many drugs can be metabolized to sulfoxide and/or sul
Autor:
Poonam Giri, Pankaj R. Patel, Nuggehally R. Srinivas, Nirmal Patel, Sanjay Singh, Lakshmikant Gupta, Brijesh Kumar Srivastva, Ranjit C. Desai
ZYTP1 is a novel Poly (ADP-ribose) polymerase protein inhibitor being developed for cancer indications.The focus of the work was to determine if ZYTP1 had a perpetrator role in the in vitro inhibition of cytochrome P450 (CYP) enzymes to aid dosing de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8967d09aa80d6f1df49f4019e85af5a8
Autor:
Poonam, Giri, Lakshmikant, Gupta, Sanjay, Singh, Nirmal, Patel, Nuggehally R, Srinivas, Brijesh Kumar, Srivastva, Ranjit C, Desai, Pankaj R, Patel
Publikováno v:
Xenobiotica; the fate of foreign compounds in biological systems. 49(10)
ZYTP1 is a novel Poly (ADP-ribose) polymerase protein inhibitor being developed for cancer indications. The focus of the work was to determine if ZYTP1 had a perpetrator role in the
Autor:
Prashant Delvadia, Poonam Giri, Namrata Prajapati, Vipul Joshi, Shyamkumar Giri, Pankaj R. Patel, Mukul R. Jain, Nuggehally R. Srinivas, Meera K. Ladani, Nirmal Patel, Lakshmikant Gupta
Publikováno v:
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 130
Saroglitazar, a PPAR αҮ agonist, is currently undergoing global development for the treatment of NASH and other indications. Saroglitazar showed CYP2C8 inhibition in human liver microsomes (IC50: 2.9 μM). The aim was to carry out drug-drug interac
Autor:
Jaideep Singh, Poonam Giri, Lakshmikant Gupta, Priyal Trivedi, Prashant Delvadia, Manoranjan Sharma, Abhijit Chatterjee, Nuggehally R. Srinivas, Nirmal Patel, Shekhar Kadam
Pharmacokinetics of voriconazole, an anti-fungal agent, was determined in collagen-induced arthritic (CIA) and healthy DBA/1J mice. CIA was confirmed in DBA/1J mice by clinical scoring and histological analysis.In vivo oral pharmacokinetic study (3 m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c94a2af68dcf6a2dcdd5a33415c2a8a0